medigraphic.com
ISSN 1561-2937 (Print)

2017, Number 3

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2017; 23 (3)

Contrast induced nephropathy by interventionist cardiology

Castelo VX, Borges MYR, Guevara MG, Martínez CA, Hechavarría PS, García RJL

Language: Spanish
References: 29
Page:
PDF size: 404.46 Kb.


ABSTRACT

Introduction: The damage of kidney function due to the use of contrast agents (nephropathy induced by contrast agents) has been increased in the last years because of a higher number of interventionist procedures has been performance in patients with cardiovascular or another diseases. Nephropathy induced by contrast agents is reversible, but it could delay permanency in the hospital of these patients, besides in those with high risk of kidney dysfunction, the damage could be irreversible. In the Institute of Cardiology and cardiovascular surgery carry out annually an average of 1533 interventional procedure that’s why we feel motivate to realize this medical review. Objective: To deepen in the study of nephropathy induced by contrast agents. Develop: We reviewed articles aboilables in the past 10 years related with this topic. Then we analyzed and summarized this information. Conclusions: The progressive increased of diagnostics and therapeutics procedures, using intravenous contrast agents in cardiology are related to a high morbility such as kidney dysfunction due to nephropathy induced by contrast agents.


REFERENCES

  1. Cifuentes DE, Aguirre GL. Pautas para aplicación controlada de medios de contraste endovasculares. Revista Med [Internet]. 2014 [citado 13 Mar 2016]; 22(1):78-3. Disponible en: http://www.scielo.org.co/pdf/med/v22n1/v22n1a12.pdf.

  2. Bastida Alquicira J, Motta Ramírez GA, Amezquita Pérez S, Gómez Vázquez JA. Donde el arte y la ciencia se unen: la nefropatía inducida por medio de contraste y sus factores de riesgo asociados. Med Int Méx. 2015 Ene-Feb; 31(1):64-76.

  3. Bernis Carro C. Guías SEN Actuación en el Fracaso Renal Agudo. Prevención de la nefropatía por contraste. Nefrología [Internet]. 2007 [citado 14 Oct 2016]; 27Supl 3:S49-7. Disponible en: http://www.senefro.org.

  4. Mehran R, Nikolsky E. Contrastinduced nephropathy: definition, epidemiology, and patients at risk. Kidney Int [Internet]. 2006 Apr [cited 2016 Jan 26]; 69 (Suppl 100):S11-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16612394.

  5. Bellomo R, Ronco C, Kellum JA, Palevsky P and the ADQI workgroup. Research acute renal failure definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care [Internet]. 2004 Aug [cited 2016 Nov 12]; 8(4): [About 204-12 p.]. Available from: http://ccforum.com/content/8/4/R204.

  6. Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant [Internet]. 2012 [cited 2016 Nov 12]; 27(12): [About 4263-72 p.]. Available from: http://ndt.oxfordjournals.org/.

  7. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG and the Acute Kidney Injury Network. Research acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Critical Care [Internet]. 2007 [cited 2016 Nov 12]; 11(2): [About 1-8 p.]. Available from: http://ccforum.com/content/11/2/R31.

  8. Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDOQI US Commentary on the 2012 KDIGO. Clinical practice guideline for acute kidney injury [editorial]; Am J Kidney Dis [Internet]. 2013 [cited 2016 Nov 15]; 61(5): [about 686 p.]. Available from: http://dx.doi.org/10.1053/j.ajkd.2013.02.349.

  9. Ferreira Morales JL. Actualidad en nefropatía por medio de contraste. Nefrollatinoam [Internet]. 2017 [citado 10 Mar 2017]; 14(2):69-78. Disponible en: http://www.elsevier.es/nefrolatinoamericana.

  10. Bonadio Aoki B, Fram D, Taminato M, Sayad Batista RE, Belasco A, Barbosa DA. Insuficiencia renal aguda después de un examen con contraste entre personas de edad avanzada. Rev. Latino-Am. Enfermagem [Internet]. 2014 jul-ago [citado 18 Nov 2016]; 22(4):637-44. Disponible en: www.eerp.usp.br/rlae.

  11. Sadat Umar, Usman A, Boyle JR, Hayes PD, Solomon RJ. Contrast medium induced acute kidney injury. Cardiorenal Med [Internet]. 2015 [cited 2017 Jan 12]; 5: [About 219-28 p.]. Available from: www.karger.com/crm.

  12. Kidney disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical practice guideline for acute kidney injury. Kidney inter [Internet]. 2012 Mar [cited 2016 Nov 12]; 2 Suppl 1:S69-88. Available from: http://www.kidney-international.org.

  13. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation [Internet]. 2002 May [cited 2016 Jan 12]; 105(19):[About 2259-64 p.]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12010907.

  14. López López B, Pérez López MJ, García Rincón A, Vázquez Vega B. Evolución de nefropatía por contraste en pacientes con enfermedad renal crónica sometidos a intervención coronaria percutánea. Rev Med Inst Mex Seguro Soc. 2015; 53(4):484-8.

  15. Górriz Teruel JL, Beltrán Catalán S. Valoración de afección renal, disfunción renal aguda e hiperpotasemia por fármacos usados en Cardiología y nefrotoxicidad por contrastes. Rev. Esp Cardiol [Internet]. 2011 [citado 24 feb 2017]; 64(12):1182-92. Disponible en: http://www.revespcardiol.org.

  16. López de Sa y Areses E, Salvador Montañés O, López de Sa y Areses E, Iniesta Manjavacas AM, Rey Blas JR, Armada Romero E, et al. Validación del score de Mehran como predictor del riesgo de nefropatía por contraste en el síndrome coronario agudo [Resumen]. Rev Esp Cardiol [Internet]. 2011 [citado 14 Ene 2017]; 64(Supl 3):[aprox. 170 p.]. Disponible en: http://www.revespcardiol.org.

  17. Fernández Cimadevilla OC, Barriales Álvarez V, Martínez Luengas IL. Nefropatía inducida por contraste. MedClin (Barc) [Internet]. 2011 [citado 22 Ene 2016]; 137(2):84-90. Disponible en: http://www.elsevier.es.

  18. Górriz Teruel JL, Beltrán Catalán S. Valoración de afección renal, disfunción renal aguda e hiperpotasemia por fármacos usados en cardiología y nefrotoxicidad por contrastes. Rev. Esp Cardiol [Internet]. 2011 [citado 24 Feb 2017]; 64(12):1182-92. Disponible en: http://www.revespcardiol.org.

  19. Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y, et al. Low hematocrit predicts contrast induced nephropathy after percutaneous coronary interventions. Kidney Int [Internet]. 2005 Feb [cited 2016 Jan 11]; 67(2): [About 706-13 p.]. Available from: http://ac.els-cdn.com/S0085253815505073/1-s2.0-S0085253815505073-main.pdf.

  20. Wybraniec MT, Mizia-Stec K. Renalase and biomarkers of contrast-induced acute kidney injury. Cardiorenal Med [Internet]. 2016 [cited 2017 Feb 12]; 6: [About 25-36 p.]. Available from: www.karger.com/crm.

  21. Sendeski M, Patzak A, Persson PB. Constriction of the vasa recta, the vessels supplying the area at risk for acute kidney injury, by four different iodinated contrast media, evaluating ionic, non-ionic, monomeric and dimeric agents. J. Invest. Radiol [Internet]. 2010 [cited 2017 Feb 10]; 45: [About 453-7 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687533/pdf/radiol.2513081732.pdf.

  22. Mehran R. A Simple Risk Score for Prediction of Contrast-Induced Nephropathy After Percutaneous Coronary Intervention. JACC [Internet]. 2004 Oct [cited 2016 Nov 17]; 44(7): [About 1393-9 p.]. Available from: http://www.onlinejacc.org/content/accj/44/7/1393.full.pdf.

  23. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al. Renal insufficiency after contrast media administration trial II (REMEDIAL II): Renal guard system in high risk patients for contrast induced acute kidney injury. Circulation [Internet]. 2011 [cited 2017 Feb 15]; 124: [About 1260-9 p.]. Available from: http://circ.ahajournals.org/content/124/11/1260.long.

  24. Seeliger E, Ladwig M, Sargsyan L, Cantow K, Persson PB, Flemming B. Proof of principle: hydration by low smolar mannitol glucose solution alleviates undesirable renal effects of an isoosmolar contrast medium in rats. Invest Radiol [Internet]. 2012 [cited 2017 Apr 14];47:[About 240-6 p.]. Available from: http://eurheartj.oxfordjournals.org/.

  25. Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. JACC [Internet]. 2012 Jan [cited 2017 Feb 5]; 5(1): [About 90-7 p.]. Available from: http://www.sciencedirect.com/science/article/pii/S1936879811007874.

  26. Revilla Martí P, Linares Vicente JA, Lukic A, Artero Bello P, Bascompte Claret R, Matajira Chia T, et al. Profilaxis de la nefropatía inducida por contraste en pacientes de alto riesgo con síndrome coronario agudo sin elevación del segmento ST. CorSalud [Internet]. 2012 [citado 25 Oct 2016]; 4(3):151-6. Disponible en: https://dialnet.unirioja.es/descarga/articulo/4258607.pdf.

  27. Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, et al. Usefulness of statin pre-treatment to prevent contrast induced nephropathy and to improve long term outcome in patients undergoing percutaneous coronary intervention [Abstract]. Am J Cardiol [Internet]. 2008 [cited 2016 Oct 14]; 101: [about 279-85 p.]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18237585.

  28. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast induced nephropathy in patients with chronic renal disease [Abstract]. Am J Cardiol [Internet]. 2010 Feb [cited 2017 Jan 22]; 105(3): [about 288-92 p.]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20102936.

  29. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short term high dose atorvastatin for prevention of contrast induced nephropathy in patients undergoing coronary angiography [Abstract]. Angiology [Internet]. 2010 Oct [cited 2017 Sep 14]; 61(7): [about 711-14 p.]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20395226.




2020     |     www.medigraphic.com